Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01539291 · ClinicalTrials.gov registry record · Phase 3
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)
A Phase 3 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 161
- Enrollment target
NCT01539291 is a Phase 3 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 161 participants.
The verdict
NCT01539291, a Phase 3 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 161 participants
- Enrollment target
Study Summary
The primary objective of this extension study (GS-US-312-0117) that is a companion study to Study GS-US-312-0116 (NCT01539512), is to evaluate the effect of idelalisib on the onset, magnitude, and duration of tumor control. Randomization was done in study GS-US-312-0116, and carried forward to study GS-US-312-117.
Interventions
- DRUG Idelalisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2012-10-03 |
| Est. Completion | 2018-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01539291
The ClinicalTrials.gov registry entry for NCT01539291 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Idelalisib is the first listed.
NCT01539291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01539291 about?
NCT01539291 is a clinical study titled "Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)". The primary objective of this extension study (GS-US-312-0117) that is a companion study to Study GS-US-312-0116 (NCT01539512), is to evaluate the effect of idelalisib on the onset, magnitude, and duration of tumor control. Randomization was done in study GS-US-312-0116, and carried forward to study...
What is the current status of trial NCT01539291?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 161 participants. The study started on 2012-10-03. Estimated completion is 2018-06-29.
What interventions are being tested in trial NCT01539291?
The interventions under investigation include: Idelalisib (DRUG).
Who is sponsoring clinical trial NCT01539291?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.